
## Michael Pinkawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5482653/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Assessment of Treatment Response in Patients with Glioblastoma Using <i>O</i> -(2- <sup>18</sup> F-Fluoroethyl)-I-Tyrosine PET in Comparison to MRI. Journal of Nuclear Medicine, 2012, 53, 1048-1057.	5.0	184
2	Prognostic Value of Early [18F]Fluoroethyltyrosine Positron Emission Tomography After Radiochemotherapy in Glioblastoma Multiforme. International Journal of Radiation Oncology Biology Physics, 2011, 80, 176-184.	0.8	132
3	A Multi-institutional Clinical Trial of Rectal Dose Reduction via Injected Polyethylene-Glycol Hydrogel During Intensity Modulated Radiation Therapy for Prostate Cancer: Analysis of Dosimetric Outcomes. International Journal of Radiation Oncology Biology Physics, 2013, 87, 81-87.	0.8	121
4	Stereotactic Body Radiation Therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlentherapie Und Onkologie, 2011, 187, 245-251.	2.0	116
5	Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiotherapy and Oncology, 2011, 100, 436-441.	0.6	105
6	Application technique: placement of a prostate–rectum spacer in men undergoing prostate radiation therapy. BJU International, 2012, 110, E647-52.	2.5	97
7	Erectile Dysfunction After External Beam Radiotherapy for Prostate Cancer. European Urology, 2009, 55, 227-236.	1.9	88
8	Prostate position variability and dose–volume histograms in radiotherapy for prostate cancer with full and empty bladder. International Journal of Radiation Oncology Biology Physics, 2006, 64, 856-861.	0.8	86
9	Prognostic impact of postoperative, pre-irradiation 18F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiotherapy and Oncology, 2011, 99, 218-224.	0.6	82
10	An overlapâ€volumeâ€histogram based method for rectal dose prediction and automated treatment planning in the external beam prostate radiotherapy following hydrogel injection. Medical Physics, 2013, 40, 011709.	3.0	72
11	Dose-escalation using intensity-modulated radiotherapy for prostate cancer – Evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiotherapy and Oncology, 2009, 93, 213-219.	0.6	68
12	Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial. Radiation Oncology, 2014, 9, 96.	2.7	67
13	Spacer stability and prostate position variability during radiotherapy for prostate cancer applying a hydrogel to protect the rectal wall. Radiotherapy and Oncology, 2013, 106, 220-224.	0.6	64
14	ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. Radiotherapy and Oncology, 2019, 141, 5-13.	0.6	62
15	Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiation Oncology, 2012, 7, 14.	2.7	61
16	Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme - a dosimetric comparison. Radiation Oncology, 2009, 4, 57.	2.7	59
17	Low-grade toxicity after conformal radiation therapy for prostate cancer—impact of bladder volume. International Journal of Radiation Oncology Biology Physics, 2006, 64, 835-841.	0.8	57
18	Association of the Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer. JAMA Network Open, 2020, 3, e208221.	5.9	56

#	Article	IF	CITATIONS
19	Image-guided radiotherapy for prostate cancer. Strahlentherapie Und Onkologie, 2008, 184, 679-685.	2.0	52
20	Influence of the initial rectal distension on posterior margins in primary and postoperative radiotherapy for prostate cancer. Radiotherapy and Oncology, 2006, 81, 284-290.	0.6	49
21	Toxicity Profile With a Large Prostate Volume After External BeamÂRadiotherapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 70, 83-89.	0.8	47
22	Bladder extension variability during pelvic external beam radiotherapy with a full or empty bladder. Radiotherapy and Oncology, 2007, 83, 163-167.	0.6	46
23	Intensity-Modulated Radiotherapy for Prostate Cancer Implementing Molecular Imaging with 18F-Choline PET-CT to Define a Simultaneous Integrated Boost. Strahlentherapie Und Onkologie, 2010, 186, 600-606.	2.0	46
24	Combination of Dose Escalation with Technological Advances (Intensity-Modulated and Image-Guided) Tj ETQq0 C Strahlentherapie Und Onkologie, 2011, 187, 479-484.	) 0 rgBT / 2.0	Overlock 10 46
25	In vivo versus in vitro individual radiosensitivity analysed in healthy donors and in prostate cancer patients with and without severe side effects after radiotherapy. International Journal of Radiation Biology, 2012, 88, 405-413.	1.8	46
26	Permanent Interstitial Low-Dose-Rate Brachytherapy for Patients with Localised Prostate Cancer: A Systematic Review of Randomised and Nonrandomised Controlled Clinical Trials. European Urology, 2011, 60, 881-893.	1.9	44
27	Learning Curve in the Application of a Hydrogel Spacer to Protect the Rectal Wall During Radiotherapy of Localized Prostate Cancer. Urology, 2013, 82, 963-968.	1.0	42
28	Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study. Radiation Oncology, 2010, 5, 27.	2.7	41
29	Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer. Radiotherapy and Oncology, 2010, 96, 25-29.	0.6	41
30	Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer. Strahlentherapie Und Onkologie, 2012, 188, 917-925.	2.0	38
31	Health-related quality of life after adjuvant and salvage postoperative radiotherapy for prostate cancer – A prospective analysis. Radiotherapy and Oncology, 2008, 88, 135-139.	0.6	37
32	Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results. BJU International, 2004, 94, 805-811.	2.5	36
33	Evaluation of source displacement and dose–volume changes after permanent prostate brachytherapy with stranded seeds. Radiotherapy and Oncology, 2007, 84, 190-196.	0.6	36
34	Health-related quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate cancer – a matched-pair comparison. Radiotherapy and Oncology, 2009, 91, 225-231.	0.6	36
35	Postoperative Radiotherapy for Prostate Cancer. Strahlentherapie Und Onkologie, 2007, 183, 23-29.	2.0	35
36	SpaceOAR Hydrogel Spacer for Reducing Radiation Toxicity During Radiotherapy for Prostate Cancer. A Systematic Review. Urology, 2021, 156, e74-e85.	1.0	34

#	Article	IF	CITATIONS
37	Quality of Life After Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: 5-Year Results. International Journal of Radiation Oncology Biology Physics, 2017, 99, 374-377.	0.8	34
38	Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer- a phase II study. Radiotherapy and Oncology, 2006, 78, 41-46.	0.6	33
39	Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment. BMC Cancer, 2009, 9, 296.	2.6	33
40	Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy? A model-based approach for patient selection. Radiotherapy and Oncology, 2016, 121, 118-123.	0.6	31
41	PET and PET/CT in radiation treatment planning for prostate cancer. Expert Review of Anticancer Therapy, 2011, 11, 1035-1041.	2.4	30
42	Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume. Radiation Oncology, 2016, 11, 87.	2.7	30
43	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. Cancer Treatment Reviews, 2021, 98, 102206.	7.7	30
44	Low-dose rate brachytherapy for men with localized prostate cancer. The Cochrane Library, 2011, , CD008871.	2.8	29
45	Interdisciplinary consensus statement on indication and application of a hydrogel spacer for prostate radiotherapy based on experience in more than 250 patients. Radiology and Oncology, 2016, 50, 329-336.	1.7	29
46	Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer. Strahlentherapie Und Onkologie, 2017, 193, 22-28.	2.0	29
47	Quality of Life After Whole Pelvic Versus Prostate-Only External Beam Radiotherapy for Prostate Cancer: A Matched-Pair Comparison. International Journal of Radiation Oncology Biology Physics, 2011, 81, 23-28.	0.8	28
48	Health-Related Quality of Life after Permanent Interstitial Brachytherapy for Prostate Cancer. Strahlentherapie Und Onkologie, 2006, 182, 660-665.	2.0	27
49	Changes of Dose Delivery Distribution within the First Month after Permanent Interstitial Brachytherapy for Prostate Cancer. Strahlentherapie Und Onkologie, 2006, 182, 525-530.	2.0	26
50	Dose-volume histogram evaluation of prone and supine patient position in external beam radiotherapy for cervical and endometrial cancer. Radiotherapy and Oncology, 2003, 69, 99-105.	0.6	24
51	Seed Displacements after Permanent Brachytherapy for Prostate Cancer in Dependence on the Prostate Level. Strahlentherapie Und Onkologie, 2008, 184, 520-525.	2.0	23
52	Factor Analysis of the Expanded Prostate Cancer Index Composite in a Patient Group after Primary (External Beam Radiotherapy and Permanent Iodine-125 Brachytherapy) and Postoperative Radiotherapy for Prostate Cancer. Current Urology, 2009, 2, 122-129.	0.6	23
53	Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: Comparison of dose, toxicity and cost-effectiveness. Radiotherapy and Oncology, 2017, 125, 107-112.	0.6	23
54	Hematologic changes during prostate cancer radiation therapy are dependent on the treatment volume. Future Oncology, 2014, 10, 835-843.	2.4	22

#	Article	IF	CITATIONS
55	Ultrahypofractionation of localized prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 89-96.	2.0	22
56	Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer. Urology, 2006, 68, 104-109.	1.0	21
57	Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer - predictive factors on irritative symptoms, incontinence and rectal bleeding. Radiation Oncology, 2009, 4, 36.	2.7	20
58	Rectal dosimetry following prostate brachytherapy with stranded seeds – Comparison of transrectal ultrasound intra-operative planning (day 0) and computed tomography-postplanning (day 1 vs. day 30) with special focus on sources placed close to the rectal wall. Radiotherapy and Oncology, 2009, 91, 207-212.	0.6	20
59	Spacer application for prostate cancer radiation therapy. Future Oncology, 2014, 10, 851-864.	2.4	19
60	Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer – focus on overall survival. Radiation Oncology, 2017, 12, 98.	2.7	19
61	Surgical Resection of Urological Tumor Metastases Following Medical Treatment. Deutsches Ärzteblatt International, 2012, 109, 631-7.	0.9	19
62	Application of a hydrogel spacer for postoperative salvage radiotherapy of prostate cancer. Strahlentherapie Und Onkologie, 2015, 191, 375-379.	2.0	18
63	Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET/CT. Strahlentherapie Und Onkologie, 2018, 194, 638-645.	2.0	18
64	Longâ€term followâ€up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowelâ€associated quality of life. BJU International, 2020, 126, 367-372.	2.5	16
65	Prostate-Specific Antigen Kinetics After Brachytherapy or External Beam Radiotherapy and Neoadjuvant Hormonal Therapy. Urology, 2007, 69, 129-133.	1.0	15
66	Current role of spacers for prostate cancer radiotherapy. World Journal of Clinical Oncology, 2015, 6, 189.	2.3	15
67	Prediction of radiation-induced toxicity by <i>in vitro</i> radiosensitivity of lymphocytes in prostate cancer patients. Future Oncology, 2016, 12, 617-624.	2.4	14
68	Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 109-116.	2.0	14
69	Interpreting the Clinical Significance of Quality of Life Score Changes after Radiotherapy for Localized Prostate Cancer. Current Urology, 2011, 5, 137-144.	0.6	13
70	Current standards and future directions for prostate cancer radiation therapy. Expert Review of Anticancer Therapy, 2013, 13, 75-88.	2.4	13
71	Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer. Strahlentherapie Und Onkologie, 2009, 185, 101-108.	2.0	11
72	Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity. Strahlentherapie Und Onkologie, 2015, 191, 771-777.	2.0	11

#	Article	IF	CITATIONS
73	Usefulness of a thermoplastic breast bra for breast cancer radiotherapy. Strahlentherapie Und Onkologie, 2016, 192, 609-616.	2.0	11
74	Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy. Clinical and Translational Radiation Oncology, 2019, 14, 17-24.	1.7	11
75	Radiotherapy in nodal oligorecurrent prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 575-580.	2.0	11
76	Treatment planning after hydrogel injection during radiotherapy of prostate cancer. Strahlentherapie Und Onkologie, 2013, 189, 796-800.	2.0	10
77	Fat necrosis and parenchymal scarring after breast-conserving surgery and radiotherapy with an intraoperative electron or fractionated, percutaneous boost: a retrospective comparison. Breast Cancer, 2014, 21, 409-414.	2.9	10
78	Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 589-597.	2.0	10
79	Inverse Automated Treatment Planning with and without Individual Optimization in Interstitial Permanent Prostate Brachytherapy with High- and Low-Activity 125I. Strahlentherapie Und Onkologie, 2003, 179, 417-422.	2.0	9
80	Failure to address potential bias in non-randomised controlled clinical trials may cause lack of evidence on patient-reported outcomes: a method study. BMJ Open, 2014, 4, e004720-e004720.	1.9	9
81	Quality of life up to 10Âyears after external beam radiotherapy and/or brachytherapy for prostate cancer. Brachytherapy, 2018, 17, 517-523.	0.5	9
82	Quality of Life Changes >10 Years After Postoperative Radiation Therapy After Radical Prostatectomy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 382-388.	0.8	9
83	Personalized Image-Guided Therapies for Local Malignencies: Interdisciplinary Options for Interventional Radiology and Interventional Radiotherapy. Frontiers in Oncology, 2021, 11, 616058.	2.8	9
84	The Motion: Radiotherapy for Prostate Cancer Preserves Sexual Function to a Greater Extent Than Nerve Sparing Radical Prostatectomy. European Urology, 2009, 56, 212-214.	1.9	8
85	Chromosomal Radiosensitivity Analyzed by FISH in Lymphocytes of Prostate Cancer Patients and Healthy Donors. Radiation Research, 2013, 180, 465-473.	1.5	8
86	Hydrogel spacers in prostate radiotherapy: a promising approach to decrease rectal toxicity. Future Oncology, 2017, 13, 2697-2708.	2.4	8
87	STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 33-35.	0.8	8
88	Impact of the Target Volume (Prostate Alone vs. Prostate with Seminal Vesicles) and Fraction Dose (1.8) Tj ETQq Strahlentherapie Und Onkologie, 2009, 185, 724-730.	0 0 0 rgB1 2.0	/Overlock 10 7
89	SBRT for Localized Prostate Cancer: Is it Ready for Take-Off?. International Journal of Radiation Oncology Biology Physics, 2019, 105, 618-620.	0.8	7
90	Long-Term Comparative Study on the Local Tumour Control of Different Ablation Technologies in	2.5	7

Primary and Secondary Liver Malignancies. Journal of Personalized Medicine, 2022, 12, 430.

#	Article	IF	CITATIONS
91	Urinary morbidity after permanent prostate brachytherapy – Impact of dose to the urethra vs. sources placed in close vicinity to the urethra. Radiotherapy and Oncology, 2012, 103, 247-251.	0.6	6
92	Persisting ring chromosomes detected by mFISH in lymphocytes of a cancer patient—A case report. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2013, 756, 158-164.	1.7	6
93	Development of an isotoxic decision support system integrating genetic markers of toxicity for the implantation of a rectum spacer. Acta OncolÃ <sup>3</sup> gica, 2018, 57, 1499-1505.	1.8	6
94	Quality of life more than 10Âyears after radiotherapy for localized prostate cancer—impact of time after treatment and prescription dose. Quality of Life Research, 2021, 30, 437-443.	3.1	6
95	Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy. Radiation Oncology, 2012, 7, 209.	2.7	5
96	Permanent interstitial brachytherapy for prostate cancer implementing neoadjuvant prostatic artery embolization. Brachytherapy, 2022, 21, 308-316.	0.5	5
97	Rectal morbidity after permanent interstitial brachytherapy for prostate cancer—Impact of Day 1 vs. Day 30 computed tomography–based postimplant dosimetry. Brachytherapy, 2010, 9, 1-7.	0.5	4
98	Transurethral resection of the prostate after radiotherapy for prostate cancer: Impact on quality of life. International Journal of Urology, 2014, 21, 899-903.	1.0	4
99	Radiotherapy. Deutsches Ärzteblatt International, 2018, 115, 596.	0.9	4
100	Zoledronic Acid in First-Line Treatment of Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 6-8.	0.8	3
101	Spinal Cord Reirradiation:Balancing Benefit Against Risks. International Journal of Radiation Oncology Biology Physics, 2021, 109, 312-313.	0.8	3
102	Interstitial single fraction brachytherapy for malignant pulmonary tumours. Strahlentherapie Und Onkologie, 2021, 197, 416-422.	2.0	3
103	Consequential late effects up to >10Âyears following primary and postoperative radiotherapy for prostate cancer. Radiotherapy and Oncology, 2021, 156, 188-192.	0.6	3
104	Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries. Strahlentherapie Und Onkologie, 2021, 197, 993-1000.	2.0	3
105	Salvage Treatment Options for Recurrent Seminoma?. International Journal of Radiation Oncology Biology Physics, 2017, 99, 510.	0.8	2
106	Interventional therapy in malignant conditions of the prostate. Der Radiologe, 2019, 59, 28-39.	1.7	2
107	Treatment of Locally Advanced Prostate Cancer: A Case Report and Narrative Review. Case Reports in Urology, 2012, 2012, 1-4.	0.3	1
108	Prediction of survival outcomes following postoperative radiotherapy after radical prostatectomy for prostate cancer. Acta Oncológica, 2020, 59, 157-163.	1.8	1

#	Article	IF	CITATIONS
109	MP46-19 MULTICENTER PHASE II TRIAL OF PERIRECTAL HYDROGEL SPACER APPLICATION IN MEN SCHEDULED FOR DOSE ESCALATION PROSTATE RADIOTHERAPY. Journal of Urology, 2014, 191, .	0.4	0
110	Dosimetric Verification of HDR Brachytherapy Treatment Plans of Three Different Entities Based on Measurements with a 2D-Array. Brachytherapy, 2019, 18, S113.	0.5	0
111	Dosimetric Comparison of Different Dose Calculation Algorithms in CT-Based Interstitial HDR Brachytherapy. Brachytherapy, 2019, 18, S114.	0.5	Ο
112	Strahlentherapie: Organspezifische Komplikationen. , 2021, , 431-451.		0
113	A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during IMRT for prostate cancer: Analysis of dosimetric outcomes Journal of Clinical Oncology, 2013, 31, 35-35.	1.6	Ο
114	Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: A pooled prospective evaluation of quality of life Journal of Clinical Oncology, 2019, 37, 39-39.	1.6	0